Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Body Weight Reduction and Metabolic/Biochemical Parameters in Overweight or Obesity

8 czerwca 2026 zaktualizowane przez: Medical University of Silesia

The Effect of Body Weight Reduction on Selected Metabolic and Biochemical Parameters in Individuals With Overweight or Obesity

This was a single-center prospective observational cohort study conducted in Poland in the context of routine metabolic outpatient care. The study assessed selected metabolic, biochemical, oxidative-stress, inflammatory, and body-composition parameters in individuals with overweight or obesity undergoing standard lifestyle-based body weight reduction management. Participants with BMI > 25 kg/m² were followed before and after body weight reduction, while individuals with normal body weight served as a comparison group. The weight reduction management included individualized dietary recommendations, physical-activity guidance, health education, regular follow-up visits, fasting blood sampling, and body-composition assessment. The aim of the study was to evaluate whether body weight reduction is associated with changes in metabolic and biochemical parameters, with particular attention to glucose and lipid metabolism, oxidative stress, inflammatory markers, adipokines, cytokines, and body-composition changes.

Przegląd badań

Szczegółowy opis

This was a single-center prospective observational cohort study conducted at the Medical University of Silesia in Katowice, Poland, and in a metabolic outpatient clinic in Miasteczko Śląskie, Poland. The study was designed to evaluate the effect of body weight reduction on selected metabolic, biochemical, oxidative-stress, inflammatory, and body-composition parameters in individuals with overweight or obesity.

The study was conducted in the context of routine metabolic outpatient care. Participants with overweight or obesity received standard lifestyle-based body weight reduction management, including individualized dietary recommendations, physical-activity guidance, health education, and regular follow-up visits. The investigators did not assign participants to an investigational medicinal product, medical device, dietary supplement, surgical procedure, pharmacological intervention, or experimental therapy. The study prospectively observed participants receiving routine lifestyle-based weight reduction management and assessed changes in clinical and laboratory parameters before and after body weight reduction.

The approved study protocol planned the inclusion of individuals with overweight or obesity and a normal-weight comparison group. Participants with BMI > 25 kg/m² were evaluated in relation to body weight reduction, while individuals with normal body weight served as a comparison group for selected baseline analyses. Patients with overweight or obesity were assessed by medical examination, dietary and clinical questionnaires, anthropometric measurements, body-composition analysis, and fasting blood sampling. Body-composition analysis included assessment of body weight, fat mass, fat-free mass, skeletal muscle mass, total body water, visceral fat, and related parameters. Blood samples were collected for biochemical analyses, including markers of glucose metabolism, lipid metabolism, oxidative stress, antioxidant status, inflammatory markers, adipokines, cytokines, chemokines, growth factors, and selected cardiovascular-risk parameters.

Participants with overweight or obesity were followed during standard body weight reduction management until clinically relevant weight reduction or achievement of optimal body weight. According to the original study documentation, assessments were planned before the start of weight reduction, after approximately 10% body weight reduction, and after approximately 20% body weight reduction or achievement of target body weight. Follow-up visits included body weight measurements, waist and hip circumference measurements, dietary counselling, education regarding caloric intake, and motivation to continue lifestyle modification.

The primary objective of the study was to assess whether body weight reduction in individuals with overweight or obesity is associated with changes in selected metabolic and biochemical parameters. Secondary objectives included evaluation of oxidative-stress and antioxidant-status parameters, glucose and lipid metabolism, inflammatory markers, adipokines, cytokines, and body-composition changes. The study also aimed to assess relationships between biochemical parameters and body-composition indices before and after body weight reduction.

The study was approved by the Bioethics Committee of the Medical University of Silesia in Katowice, Poland. All participants received information about the study and provided written informed consent before participation. This ClinicalTrials.gov record is submitted retrospectively to meet journal publication requirements and to provide transparent public information about the completed study.

Typ studiów

Obserwacyjny

Zapisy (Rzeczywisty)

53

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Silesian Voivodeship
      • Miasteczko Śląskie, Silesian Voivodeship, Polska, 42-610
        • Eko-Prof-Med Medical Center, Metabolic Outpatient Clinic
      • Zabrze, Silesian Voivodeship, Polska, 41-808
        • Department of Biochemistry, Faculty of Medical Sciences in Zabrze, Medical University of Silesia in Katowice

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

  • Dorosły
  • Starszy dorosły

Akceptuje zdrowych ochotników

Nie

Metoda próbkowania

Próbka bez prawdopodobieństwa

Badana populacja

Adults with overweight or obesity who received routine lifestyle-based body weight reduction management in a metabolic outpatient clinic in Miasteczko Śląskie, Poland, and who provided written informed consent for participation in the study.

Opis

Inclusion Criteria:

  • Adults aged 18-85 years
  • BMI > 25 kg/m²
  • Overweight or obesity diagnosed on the basis of medical examination and body-composition assessment
  • Participation in routine lifestyle-based body weight reduction management in a metabolic outpatient clinic
  • Written informed consent to participate in the study

Exclusion Criteria:

  • Lack of informed consent
  • Severe hepatic insufficiency
  • Severe renal insufficiency
  • Severe respiratory insufficiency
  • Severe circulatory insufficiency
  • Disturbances of consciousness
  • Treatment-resistant depression
  • Chronic alcohol abuse
  • Pregnancy
  • History of serious nervous system injury
  • Implanted cardiac pacemaker
  • Pharmacological treatment affecting glucose and/or lipid metabolism
  • Incomplete follow-up or incomplete laboratory data

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

Kohorty i interwencje

Grupa / Kohorta
Interwencja / Leczenie
Individuals With Overweight or Obesity
Adults with BMI > 25 kg/m² who were receiving routine lifestyle-based body weight reduction management in a metabolic outpatient clinic. Participants were prospectively observed and assessed before and after body weight reduction. Assessments included clinical and dietary questionnaires, anthropometric measurements, body-composition analysis, fasting blood sampling, and biochemical, metabolic, oxidative-stress, inflammatory, adipokine, and cytokine measurements.
Standard lifestyle-based body weight reduction management received as part of routine metabolic outpatient care. It included individualized dietary recommendations, physical-activity guidance, health education, and regular follow-up visits. Participants were not assigned to this management as part of the study; the study prospectively observed patients receiving routine care and assessed metabolic, biochemical, inflammatory, oxidative-stress, adipokine, cytokine, and body-composition parameters before and after body weight reduction.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Change in Body Weight
Ramy czasowe: Baseline and after body weight reduction, up to approximately 6 months
Change in body weight from baseline to follow-up after routine lifestyle-based body weight reduction management.
Baseline and after body weight reduction, up to approximately 6 months

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Change in Body Fat Mass
Ramy czasowe: Baseline and after body weight reduction, up to approximately 6 months
Change in body fat mass assessed by bioelectrical impedance analysis and expressed in kilograms.
Baseline and after body weight reduction, up to approximately 6 months
Change in Glucose concentration in mg/dl.
Ramy czasowe: Baseline and after body weight reduction, up to approximately 6 months
Changes in fasting glucose.
Baseline and after body weight reduction, up to approximately 6 months
Change in total-cholesterol concentration in mg/dl.
Ramy czasowe: Baseline and after body weight reduction, up to approximately 6 months
Changes in total cholesterol concentration.
Baseline and after body weight reduction, up to approximately 6 months
Change in malondialdehyde concentration in μmol/l.
Ramy czasowe: Baseline and after body weight reduction, up to approximately 6 months
Change in blood malondialdehyde concentration, assessed as a marker of lipid peroxidation and oxidative stress, from baseline to follow-up after body weight reduction.
Baseline and after body weight reduction, up to approximately 6 months
Change in serum IL-6 concentration in pg/ml.
Ramy czasowe: Baseline and after body weight reduction, up to approximately 6 months
Change in serum interleukin-6 (IL-6) concentration from baseline to follow-up after body weight reduction. IL-6 was measured in serum samples as a marker of systemic low-grade inflammation and expressed in pg/ml.
Baseline and after body weight reduction, up to approximately 6 months

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Śledczy

  • Główny śledczy: Sławomir Kasperczyk, Prof, Medical University of Silesia in Katowice

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Publikacje ogólne

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

10 maja 2016

Zakończenie podstawowe (Rzeczywisty)

30 września 2022

Ukończenie studiów (Rzeczywisty)

30 września 2022

Daty rejestracji na studia

Pierwszy przesłany

2 czerwca 2026

Pierwszy przesłany, który spełnia kryteria kontroli jakości

8 czerwca 2026

Pierwszy wysłany (Rzeczywisty)

12 czerwca 2026

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

12 czerwca 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

8 czerwca 2026

Ostatnia weryfikacja

1 czerwca 2026

Więcej informacji

Terminy związane z tym badaniem

Inne numery identyfikacyjne badania

  • KNW/0022/KB1/19/I/16
  • Secondary ID: KNW-1-016/N/7/2 (Inny numer grantu/finansowania: Medical University of Silesia)
  • Secondary ID: KNW-1/109/K/8/Z (Inny identyfikator: Medical University of Silesia)
  • Secondary ID: KNW-1/171/K/9/O (Inny identyfikator: Medical University of Silesia)
  • Secondary ID: PCN-1-049/K/0/O (Inny identyfikator: Medical University of Silesia)
  • Secondary ID: PCN-1-018/K/1/O (Inny identyfikator: Medical University of Silesia)
  • Secondary ID: PCN-1-132/K/2/O (Inny identyfikator: Medical University of Silesia)

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

NIE

Opis planu IPD

Individual participant data will not be made publicly available because of privacy and confidentiality restrictions, limitations of the original informed consent, and the retrospective registration of this completed study. De-identified aggregate data or non-identifiable datasets may be made available from the investigators upon reasonable request, subject to institutional approval and applicable data protection regulations.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Nie

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj